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An efficient modular approach toward medicinally important 5-acylamino-4,5-isoxazolines via the
1,3-dipolar cycloaddition reaction of nitrile oxides and MCR-derived enamide building blocks is
described. This approach results in isoxazolines containing four elements of diversity utilizing two
practically simple synthetic operations.
 2016 Elsevier Ltd. All rights reserved.Synthetic methods that deliver, within a number of convergent ical targets, including tyrosine phosphatase 1B,7 macrophage
steps, medicinally important scaffolds while allowing for full and
independent control over the peripheral moieties, are of particular
importance to medicinal chemistry research.1 Such methods
enable the time- and cost-efficient synthesis of lead compound
analogs which is a pre-requisite to understanding structure–activ-
ity relationships2 as well as offering a clear advantage over tradi-
tional linear sequences which typically involve scaffold
decoration with appendages in the last step.
Multicomponent chemistry provides a uniquely suitable tool-
box for the development of such methods. Indeed, the nature of
the molecular scaffold is determined by the specific multicompo-
nent reaction (MCR) as well as various skeleton-defining post-
MCR modifications, while the periphery—by a specific selection
of reagents for the synthetic array. Prominent MCRs such as the
Ugi3 or Castagnoli-Cushman4 reactions have a large enough scope
to permit a wide range of side-chain variations. Strategies based on
sequential MCRs introduce even more diversity elements which
can be altered to fine-tune the compounds’ desired biological
activity and suppress side-effects.5
Isoxazolines certainly deserve to be considered as privileged
cores6 for drug design, taking into account the multitude of biolog-migration inhibitory factor (MIF),8 fatty acid amide hydrolase
(FAAH),9 and M1 muscarinic acetylcholine receptors,10 which are
perturbed by isoxazoline-based compounds. Replacement of the
carbohydrate portion of nucleosides with an isoxazoline core deliv-
ered nucleoside analogs that inhibited viral reverse trascrip-
tase.11,12 Furthermore, isoxazolines13,14 are amide bond
bioisosteres and, therefore, are useful in peptidomimetic design.15
One of the most popular ways to construct the isoxazoline core
is the 1,3-dipolar cycloaddition of nitrile oxides with a carbon–car-
bon double bond.16 The cycloaddition is particularly facile for elec-
tron-rich olefins such as enamides, which can be prepared by a
range of methods.17 Notably, enamides 1 were discovered to be
principal by-products in b-lactam syntheses via ketene-imine
[2+2]-cycloaddition reactions involving a-C–H imines. Presum-
ably, this process occurred via the reaction of imines with an acyl
chloride from which a ketene is generated (Scheme 1A).18–21
Recently, we observed a similar formation of enamides 2 when
attempting a Castagnoli-Cushman reaction of a-C–H imines with
dicarboxylic acid anhydrides22 which are also strong acylating
agents (Scheme 1B). Upon reviewing the literature, it became
apparent that the reaction of acyl chlorides with a-C–H imines in
the presence of a tertiary amine HCl scavenger has gained promi-
nence as a three-component synthesis of enamides from aldehyde
precursors, with the interim formation of the respective imine
intermediates.23–27
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Scheme 1. Formation of enamides 1 and 2 in reactions involving a-C–H imines and
the use of acylating agents.
Table 1
Enamides 3a–e prepared via a three-component approach
Compound R1 R2 R3 Isolated yield 3 (%)
3a H Bn Ph 42
3b Me Bn Ph 39
3c H 4-MeC6H4CH2 4-O2NC6H4 48
3d H MeO(CH2)3 4-MeC6H4 46
3e H 3-PyCH2 Ph 41
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Scheme 3. Preparation of 5-acylamino-4,5-isoxazoles 5a–l via 1,3-dipolar cycload-
dition of nitrile oxides (generated in situ from oximes 4a–e) and enamides 3a–e.
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of isoxazoles via 1,3-dipolar cycloaddition mostly described the
use of readily available N-vinylpyrrolidone8,10,28 or N-vinylphthal-
imide,8 except for an isolated report describing the use of a cyclic
enamide synthon29 and a recent example involving enamides akin
to 1, generated via a base-promoted isomerization of N-ally-
lamides.30 Thus, it appeared that a modular approach (Fig. 1) to
constructing isoxazolines from enamide building blocks with three
independently variable elements of diversity has not been investi-
gated in connection with said three-component approach. Herein,
we report recent results from our laboratories that fill this void.
Five exemplary enamides 3a–e were prepared31 from their
respective aldehydes and primary amines via the intermediate for-
mation of an imine intermediate using MgSO4 as a dehydrating
agent. The crude imine was treated with acyl chlorides in the pres-
ence of triethylamine (MgSO4 was added to suppress possible
enamide hydrolysis by adventitious water). Formation of 3a–e
was complete within 2–18 h according to the 1H NMR spectro-
scopic analysis of reaction mixture aliquots (Scheme 2).
While the crude enamides were at least 85% pure by 1H NMR
spectroscopy, attempted use of this material in subsequent
cycloaddition reactions unexpectedly delivered a complex mixture
of products. Therefore, enamides 3a–e were purified by chro-
matography using eluents containing triethylamine to neutralize
the slightly acidic silica gel (ESI). Despite this precaution, the iso-
lated yields of 3a–e were somewhat modest (Table 1).R1 CHO
1) R2NH2, MgSO4,
DCM, 0 oC, 2-18 h
2) R3COCl, Et3N,
MgSO4, DCM
0 oC to r. t., 2-18 h
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Scheme 2. Three-component synthesis of enamides 3a–e.
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Figure 1. Modular approach to constructing 5-acylaminoisoxazolines from MCR-
derived enamides envisioned and realized in present study.Nitrile oxides were generated in situ, from a set of known
aldoximes 4 upon treatment with N-chlorosuccinimide and subse-
quent Et3N-promoted elimination of HCl, in the presence of enam-
ides 3 (Scheme 3).32
Continuing the reaction for 2–18 h (depending on the substitu-
tion pattern in 3 and 4, ESI) led to the formation of a single major
product and a number of minor by-products. Chromatographic iso-
lation of the major product provided the desired isoxazolines 5a–l
in modest to good yields (Table 2). The identity of these com-
pounds was established by 1H and 13C NMR spectroscopy as well
as high-resolution mass-spectrometry data (ESI). It should be
noted that, owing to the concerted nature of the 1,3-dipolar
cycloaddition process, compound 5e was obtained as a single cis-
isomer.
In summary, we have described an efficient modular approach
toward medicinally important 5-acylamino-4,5-isoxazolines
employing the 1,3-dipolar cycloaddition reaction of nitrile oxides
with MCR-derived enamide building blocks, resulting in the target
compounds containing four elements of diversity, utilizing two
practically simple synthetic operations. This finding will facilitate
the medicinal chemistry optimization of bioactive chemical series
based on the 5-acylamino-4,5-isoxazoline scaffolds as it permits
the independent variation of each peripheral group to explore
structure–activity relationships.Table 2
5-Acylamino-4,5-isoxazolines 5a–l
Compound R1 R2 R3 R4 Isolated
yield 5 (%)
5a H Bn Ph Et 44
5b H Bn Ph 4-MeC6H4 65
5c H Bn Ph 4-MeOC6H4 74
5d H Bn Ph 2-thienyl 44
5e Me Bn Ph 4-MeC6H4 23
5f H 4-MeC6H4CH2 4-O2NC6H4 Et 69
5g H 4-MeC6H4CH2 4-O2NC6H4 4-MeOC6H4 75
5h H MeO(CH2)3 4-MeC6H4 Et 40
5i H 3-PyCH2 Ph 4-MeC6H4 49
5j H 3-PyCH2 Ph 4-MeOC6H4 70
5k H 3-PyCH2 Ph 3-(PhO)C6H4 52
5l H 3-PyCH2 Ph 2-thienyl 35
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